CDDO-Im

CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ[1][2].

Product Specifications

CAS Number

[443104-02-7]

Product Name Alternative

RTA-403; TP-235; CDDO-Imidazolide

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ferroptosis; Keap1-Nrf2; PPAR

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CDDO-Im.html

Purity

99.30

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O

Molecular Formula

C34H43N3O3

Molecular Weight

541.72

Precautions

H302, H315, H319, H335

References & Citations

[1]Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9 (7) :2798-806.|[2]Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65 (11) :4789-98.|[3]So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9 (9) :e107616.